- Novavax (NASDAQ:NVAX +18.3%) is up on more than double normal volume. No particular news accounts for the action. Last month, it initiated a Phase 2 clinical trial assessing the safety and immunogenicity of its F-protein nanoparticle RSV F Vaccine in adults at least 60 years old.
- The 300-subject study will evaluate the performance of one- and two-dose regimens of RSV F Vaccine with and without aluminum phosphate or the company's Matrix-M adjuvant. Top-line data are expected in Q3.
- RSV infection is a significant risk for older people, affecting 2.5M Americans each year causing 207K hospitalizations and 16K deaths. There are currently no RSV vaccines commercially available.